Cargando…

Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)

As new public health challenges relating to COVID-19 emerge, such as variant strains, waning vaccine efficacy over time, and decreased vaccine efficacy for special populations (immunocompromised hosts), it is important to determine a correlate of protection (CoP) to allow accurate bridging studies f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sherman, Amy C., Desjardins, Michaël, Baden, Lindsey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563351/ https://www.ncbi.nlm.nih.gov/pubmed/35153045 http://dx.doi.org/10.1016/j.cll.2021.10.008

Ejemplares similares

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
por: Aleissa, Muneerah M., et al.
Publicado: (2023)

Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial
por: Fong, Youyi, et al.
Publicado: (2023)

Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus
por: Enjuanes, Luis, et al.
Publicado: (2010)

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease
por: Huang, Angkana T., et al.
Publicado: (2020)

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity
por: Huang, Angkana T., et al.
Publicado: (2020)

Correction to: Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial
Publicado: (2023)

Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt
por: El Rifay, Amira S., et al.
Publicado: (2021)

100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant
por: Mitre, Xhoi, et al.
Publicado: (2021)

Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary( )
por: Weitzman, Elissa R, et al.
Publicado: (2022)

Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection
por: Sajadi, Mohammad M., et al.
Publicado: (2022)

Antibodies and vaccines against Middle East respiratory syndrome coronavirus
por: Xu, Jiuyang, et al.
Publicado: (2019)

Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant
por: Desjardins, Michaël, et al.
Publicado: (2021)

Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination
por: Richterman, Aaron, et al.
Publicado: (2021)

A research and development (R&D) roadmap for broadly protective coronavirus vaccines: Setting a path to address coronavirus threats
por: Moore, Kristine A., et al.
Publicado: (2022)

European Pediatric Societies and severe acute respiratory syndrome coronavirus-2 vaccination in children under age 12 years: a different path in England?
por: Brown, Katherine L.
Publicado: (2022)

Messenger RNA vaccines and neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome
por: Streng, Bianca M M, et al.
Publicado: (2022)

Kinetics of Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Doses in Patients With Predominant Antibody Deficiency
por: DiGiacomo, Daniel, et al.
Publicado: (2023)

Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2
por: Sajna, Kuttuvan Valappil, et al.
Publicado: (2021)

Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations
por: Purcell, Ruth A., et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
por: Okba, Nisreen M.A., et al.
Publicado: (2020)

Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity
por: Brown, Jennifer A, et al.
Publicado: (2023)

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine( )
por: Maron, Jenny S, et al.
Publicado: (2022)

Characteristics and roles of severe acute respiratory syndrome coronavirus 2‐specific antibodies in patients with different severities of coronavirus 19
por: Huang, Z., et al.
Publicado: (2020)

Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series Vaccine in Pediatric Patients with Predominant Antibody Deficiency
por: Tandon, Megha, et al.
Publicado: (2023)

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus
por: Yip, Ming Shum, et al.
Publicado: (2014)

Evaluation of four commercial severe acute respiratory coronavirus 2 antibody tests
por: Ashizawa, Nobuyuki, et al.
Publicado: (2021)

Alternative Methods to Detect Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies
por: Patel, Rashmi, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Antigens as Targets of Antibody Responses
por: Ogata, Alana F., et al.
Publicado: (2022)

Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses
por: Lin, Yajie, et al.
Publicado: (2022)

Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Decedents Undergoing Forensic Postmortem Examination: Feasibility for  Real-Time Pandemic Surveillance
por: Coburn, Sally B, et al.
Publicado: (2022)

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination
por: Chen, Xuemin, et al.
Publicado: (2023)

The correlation between IgM and IgG antibodies with blood profile in patients infected with severe acute respiratory syndrome coronavirus
por: Alibolandi, Zahra, et al.
Publicado: (2022)

Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
por: Enjuanes, Luis, et al.
Publicado: (2008)

Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019
por: Regan, James, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients
por: Strauss, Alexandra T., et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Healthcare Workers After Vaccine Administration in an Intensive Care Unit
por: Lemos, Cláudia, et al.
Publicado: (2021)

Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency
por: Barmettler, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s28v05cfadh0uekpncqqchmjda